Pembrolizumab (Pembro) vs Placebo (Pbo) as Second-Line Treatment for Sorafenib-Treated Advanced Hepatocellular Carcinoma (aHCC): 4.5-Year Follow-Up From KEYNOTE-240
Pembrolizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pembrolizumab (Pembro) vs Placebo (Pbo) as Second-Line Treatment for Sorafenib-Treated Advanced Hepatocellular Carcinoma (aHCC): 4.5-Year Follow-Up From KEYNOTE-240 ### Output: Pembrolizumab